ClinicalTrials.gov
ClinicalTrials.gov Menu

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03132155
Recruitment Status : Recruiting
First Posted : April 27, 2017
Last Update Posted : August 13, 2018
Sponsor:
Information provided by (Responsible Party):
NantPharma, LLC

Brief Summary:
This is a phase 2 study that will assess the efficacy of AMG 337 in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion.

Condition or disease Intervention/treatment Phase
Clear Cell Sarcoma Drug: AMG 337 Phase 2

Detailed Description:
The phase 2 study will assess efficacy of AMG 337 in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion. The study will be conducted using Simon's two-stage optimal design. The null hypothesis of Simon's two-stage design states that the ORR will be ≤ 40% (poor response) and will be tested against a one-sided alternative.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion
Actual Study Start Date : May 2, 2018
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Experimental: AMG 337
AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
Drug: AMG 337
6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 1 year ]
    Confirmed ORR (confirmed complete response or partial response) will be evaluated in accordance with RECIST Version 1.1.


Secondary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability) [ Time Frame: 1 year ]
    To evaluate the safety of AMG 337 based on grade 3 or 4 non-hematologic toxicity.

  2. Progression-free Survival (PFS) [ Time Frame: 1 year ]
    To determine PFS, evaluated in accordance with RECIST Version 1.1.

  3. Overall Survival (OS) [ Time Frame: 1 year ]
    To determine OS, defined as the time from the date of the first administration of therapy to the date of death.

  4. Duration of Response (DOR) [ Time Frame: 1 year ]
    To determine DOR, measured by RECIST Version 1.1.

  5. Disease Control Rate (DCR) [ Time Frame: 4 months ]
    To determine DCR (confirmed CR, PR, or SD) lasting for at least 4 months.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
  2. Able to attend required study visits and return for adequate follow-up, as required by this protocol.
  3. Able to self-administer AMG 337 as a whole capsule by mouth every day.
  4. Age ≥ 16 years.
  5. Histologically confirmed, unresectable, locally advanced or metastatic tumors that contain the EWSR1-ATF1 gene fusion, as determined by fluorescent in situ hybridization (FISH) and confirmed by RNA sequencing (RNAseq).
  6. Have measurable disease evaluable in accordance with RECIST Version 1.1.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  8. Must have a recent Formalin-fixed paraffin-embedded (FFPE) tumor biopsy specimen that was obtained following the conclusion of the most recent anticancer treatment. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period.
  9. Must be willing to undergo a biopsy during the treatment period, if considered safe by the investigator.
  10. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  11. Hematologic function, as follows:

    1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.
    2. Platelet count ≥ 50 × 109/L.
    3. Hemoglobin > 8 g/dL.
    4. Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 × upper limit of normal (ULN), except for subjects on anticoagulation therapy for venous thromboembolism.
  12. Renal function, as follows:

    a. Calculated creatinine clearance > 30 mL/min.

  13. Hepatic function, as follows:

    1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 × ULN and total bilirubin < 1.5 × ULN.
    2. Alkaline phosphatase (ALP) < 2 × ULN (≤ 5 × ULN if bone or liver metastases are present)
  14. Agreement to practice effective contraception (both male and female subjects, if the risk of conception exists).

Exclusion Criteria:

  1. Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
  2. Inability to attend required study visits and return for adequate follow-up, as required for this protocol.
  3. Known hypersensitivity to any component of the study medication(s).
  4. Women who are nursing, pregnant, or planning to become pregnant during the duration of the study.
  5. Current diagnosis or history of a second neoplasm, except the following:

    a. Adequately treated non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 2 years.

  6. History of bleeding diathesis.
  7. Uncontrolled hypertension (systolic > 160 mmHg and/or diastolic > 100 mmHg) or clinically significant cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months before study day 1; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication.
  8. Baseline ECG Fridericia's formula QTcF > 470 ms.
  9. Active infection requiring intravenous (IV) antibiotics within 2 weeks before study day 1.
  10. Significant gastrointestinal disorder (eg, Crohn's disease, ulcerative colitis, extensive gastrointestinal resection) that in the opinion of the Investigator may influence drug absorption.
  11. Positive result of screening test for human immunodeficiency virus (HIV).
  12. Evidence of acute hepatitis B and C. Subjects with chronic hepatitis B or C are eligible if their condition is stable and, in the opinion of the investigator, would not pose a risk to subject safety.
  13. Toxicities from prior anti-tumor therapy not resolved to CTCAE Version 4.03 grade 0 or 1.

    a. Grade 2 toxicities from prior anti-tumor therapy that are considered irreversible (defined as having been present or stable for > 4 weeks), such as stable grade 2 peripheral neuropathy or ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria.

  14. Participation in this study or in an investigational study and/or procedure with any molecularly targeted agents reported to inhibit Mesenchymal epithelial transition factor (MET) within 14 days before study day 1.
  15. Anti-tumor therapy, including chemotherapy, antibody therapy, retinoid therapy, or other investigational therapy within 14 days before study day 1.
  16. Therapeutic or palliative radiation therapy within 14 days before study day 1.
  17. Major surgery within 28 days before study day 1.
  18. Any comorbidity that in the opinion of the investigator may increase the risk of toxicity.
  19. Concurrent or prior use of a strong CYP3A4 inhibitor within 14 days before study day 1, including the following: ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole.
  20. Concurrent or prior ingestion of grapefruit or grapefruit products, or other foods known to inhibit CYP3A4 within 7 days before study day 1.
  21. Concurrent or prior use of strong CYP3A4 inducers within 28 days before study day 1, including the following: phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, or the herbal supplement St. John's Wort.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03132155


Contacts
Contact: NantKWest Clinical Review Team 800-988-6083 clinical.trials@NantKwest.com

Locations
United States, California
Chan Soon-Shiong Institute for Medicine Recruiting
El Segundo, California, United States, 90245
Sponsors and Collaborators
NantPharma, LLC

Responsible Party: NantPharma, LLC
ClinicalTrials.gov Identifier: NCT03132155     History of Changes
Other Study ID Numbers: QUILT-3.031
First Posted: April 27, 2017    Key Record Dates
Last Update Posted: August 13, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Sarcoma
Sarcoma, Clear Cell
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Connective Tissue